文献速递浆细胞疾病

如何治疗三药耐药多发性骨髓瘤

How I treat triple-class refractory multiple myeloma.
PubMed 文献 · Br J Haematol · 2022-04-03

免疫调节酰亚胺药物、蛋白酶体抑制剂和抗CD38单克隆抗体是多发性骨髓瘤治疗的三大支柱。对这三类药物均耐药(三药耐药)的患者预后 historically 差,观察性研究显示现有治疗的总缓解率约30%,总生存期不足1年。虽无随机试验,但单臂试验显示抗BCMA CAR-T、抗BCMA抗体药物偶联物、XPO1抑制剂及双特异性T细胞衔接器等新机制药物有活性。本文总结现有文献并为这类异质性患者群体提供治疗选择的一般性指导。

要点

  • 三药耐药多发性骨髓瘤患者现有治疗总缓解率约30%,总生存期不足1年。
  • 抗BCMA CAR-T、抗BCMA抗体药物偶联物和XPO1抑制剂在单臂试验中显示活性。
  • 抗BCMA双特异性T细胞衔接剂和非BCMA双特异性T细胞衔接剂在多数患者中显示活性。

核心结论

  • 三药耐药多发性骨髓瘤预后 historically 差,现有治疗总缓解率约30%,总生存期不足1年。
  • 多种新机制药物在单臂试验中显示活性,但尚无随机试验完成。
  • 本文总结现有文献并为这类异质性患者提供治疗选择的一般性指导。

研究设计与样本

  • 综述类文章,总结现有文献并提供一般性指导。

主要发现

  • 观察性研究显示现有治疗的总缓解率约30%,总生存期不足1年。
  • 抗BCMA CAR-T、抗BCMA抗体药物偶联物和XPO1抑制剂在单臂试验中显示活性。
  • 抗BCMA双特异性T细胞衔接剂和非BCMA双特异性T细胞衔接剂在多数患者中显示活性。
  • venetoclax在t(11;14)多发性骨髓瘤中可能具有独特活性。

关键数值与推荐

  • 三药耐药定义为对免疫调节酰亚胺药物、蛋白酶体抑制剂和抗CD38单克隆抗体均耐药。
  • 现有治疗的总缓解率约30%,总生存期不足1年。
  • venetoclax在t(11;14)多发性骨髓瘤中可能具有独特活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Immunomodulatory imide drugs (IMiDs), proteasome inhibitors (PIs) and anti-CD38 monoclonal antibodies (MoAbs) are the pillars of modern multiple myeloma (MM) therapy. The prognosis of patients with MM that became refractory to these three classes (triple-class refractory [TCR]) is historically poor. Observational studies indicate an overall response rate of ~30% and overall survival inferior to 1 year with existing therapies. While no randomised trial has been completed in this setting, several agents exploring new mechanisms of action showed activity in TCR MM in single-arm trials, including anti-B-cell maturation antigen (BCMA) chimeric antigen receptor T cells, anti-BCMA antibody-drug conjugates and exportin 1 (XPO1) inhibitors. Among agents in development, anti-BCMA bispecific T-cell engagers (TCE), and non-BCMA TCEs demonstrated activity in most patients. Additionally, specific agents may exhibit unique activity in biologically defined patient subsets, as exemplified by venetoclax in t(11;14) MM. The main open questions in TCR MM are preferred sequence of existing therapies, the utility of sequential use of agents with similar mechanism of action, but different immunotherapy target and the relative efficacy of the different anti-BCMA platforms. Here, we summarise the existing literature and provide general guidance on selecting therapy for this challenging and heterogenous group of patients.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Costa LJ, Hungria V, Mohty M, et al. How I treat triple-class refractory multiple myeloma. Br J Haematol. 2022. PMID: 35373352. doi:10.1111/bjh.18185

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。